Back

Towards Democratizing CNS Tumor Classification: 10-fold reduction in methylation sequencing cost with the Flongle Flow Cell

Grunwald, A.; Feinberg-Gorenshtein, G.; Toledano, H.; Birger, Y.; Izraeli, S.; Ebenstein, Y.

2026-09-08 oncology
10.64898/2026.09.03.26361431 medRxiv
Show abstract

Oxford Nanopore Technologies based methylation profiling enables rapid, accurate CNS tumor classification but is currently mostly performed with MinION flow cells (~$1,000 USD). We benchmarked the low cost Flongle flow cell (~$100, 10 fold reduction) for methylation based tumor classification. Across 12 pediatric CNS tumor samples with highly variable sequencing yields (17 to 330 Mbp), both Sturgeon and nanoDx classifiers achieved perfect diagnostic accuracy when operating above significance thresholds, despite extreme data sparsity. Bootstrap analysis determined empirically defined minimum data thresholds. These results demonstrate that Flongle flow cells enable cost effective deployment of rapid, accurate nanopore based CNS diagnostics while maintaining clinical reliability.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.